Each box of 10 vials carries a Peptworks label and a unique QR → the batch CoA (HPLC + heavy metals), verified by a third party. Checkable by you and your customers.
🔗 Peptworks.euFOXO4-DRI
| Units (combined total) | Discount | €/vial | This product ×100 |
|---|---|---|---|
| 100 | — | €95,00 | €9500 |
| 300 | −18% | €77,90 | €23.370 |
| 500 | −25% | €71,25 | €35.625 |
| 1000 | −32% | €64,60 | €64.600 |
Combine any reference: the discount applies to the combined total of vials, not per product. A single tier, not stacked.
What is — FOXO4-DRI
FOXO4-DRI is a synthetic peptide supplied as a lyophilized 10 mg vial for laboratory research use only. It is a D-retro-inverso (DRI) peptide, an engineered variant built from D-amino acids in reversed sequence to improve stability against proteolysis in experimental settings. In the research literature it is classified as a senolytic tool compound, used to study the selective elimination of senescent cells in vitro and in preclinical models. Peptworks offers it to B2B resellers as unbranded bulk vials or as white-label product, with EU-based stock, >=98% HPLC purity and an independent per-batch Certificate of Analysis. It is not a medicine, supplement, cosmetic or medical device and is not intended for human or animal use.
In published research models, FOXO4-DRI is designed to interfere with the interaction between the transcription factor FOXO4 and the tumor-suppressor protein p53 inside senescent cells. Senescent cells are reported to rely on FOXO4 to sequester p53 and evade apoptosis; by acting as a competitive peptide that perturbs the FOXO4-p53 interface, FOXO4-DRI is studied for its capacity to release p53 and trigger apoptosis preferentially in senescent cells while sparing non-senescent cells. This selective pro-apoptotic behavior in senescent populations is the basis for its use as a senolytic research reagent. All mechanistic descriptions here refer strictly to in-vitro and animal experimental systems, not to any human application.
Research
- Cellular senescence and senolytic screening in vitro
- FOXO4-p53 protein-protein interaction studies
- p53-dependent apoptosis pathways in senescent cell cultures
- Aging and tissue-homeostasis models in laboratory animals
- Senescence-associated secretory phenotype (SASP) investigations
- Fibrosis, metabolic and chemotoxicity-related senescence models
- Peptide stability and D-retro-inverso design research
Advantages
- Reported selective induction of apoptosis in senescent cell populations in preclinical models
- Used as a reference senolytic tool compound for comparing senescent-cell clearance strategies
- D-retro-inverso design studied for improved peptide stability in experimental media
- Enables investigation of FOXO4-p53 disruption as a mechanistic target
- Supports controlled, reproducible research when supplied with per-batch CoA and >=98% HPLC purity
Safety
- In animal studies, transient reactions at injection sites have been described in the research literature
- Off-target or dose-dependent cytotoxicity toward non-senescent cells is a documented consideration in experimental design
- Reported variability of senolytic response across cell types and models
- As a research reagent, handling requires standard laboratory safety practices; toxicological profile in humans is not established
Ideal for
- Academic and industrial research laboratories studying cellular senescence
- Longevity and aging-biology research programs
- Resellers building a research-peptide catalog under their own brand (white-label)
- Distributors needing EU-stocked, CoA-backed bulk supply
- Comparative senolytic mechanism-of-action studies in vitro and in preclinical animal models
This product is a laboratory reagent supplied strictly for research. It is not a medicine, food or supplement and is not for human or veterinary use. It must be handled by qualified professionals under laboratory conditions.
Frequently asked questions
Where can I buy FOXO4-DRI in bulk in the EU?
Peptworks is a B2B wholesale and white-label supplier with FOXO4-DRI (10 mg lyophilized vial) already stocked inside the EU. Orders ship intra-community in 3-5 business days with no customs. Minimum order is 10 units (one box of 10) per reference, sold for laboratory research use only. Payment is by USDC bank transfer or invoice.
What is the wholesale FOXO4-DRI price per vial?
FOXO4-DRI (10 mg) is priced per vial with combined-volume discounts on the whole order: EUR 99.00/vial at 100 units, EUR 81.18/vial at 300 units (-18%), EUR 74.25/vial at 500 units (-25%) and EUR 67.32/vial at 1000 units (-32%). The discount is a single tier based on your combined total units, not stacked.
Can I order white-label FOXO4-DRI with my own brand?
Yes. You can buy FOXO4-DRI as unbranded bulk vials or as white-label, labelled with your own brand and boxed. A one-time label setup fee of EUR 180 applies to orders under 100 units and is free from 100 units. Every box carries a Peptworks label with a unique QR that links to that batch's Certificate of Analysis.
What is the minimum order for FOXO4-DRI?
The minimum order is 10 units per reference, which is one box of 10 vials. Vials always ship in boxes of 10. You can combine references across your order, and volume pricing is calculated on the combined total number of units.
How is the FOXO4-DRI Certificate of Analysis verified?
Each batch is tested independently by HPLC (>=98% purity) and for heavy metals, and ships with a per-batch Certificate of Analysis. The box carries a unique QR that links to that batch's CoA, which you can authenticate through Peptworks. This lets your customers verify identity, purity and batch traceability.
Is FOXO4-DRI from Peptworks for human use?
No. FOXO4-DRI is supplied strictly as a laboratory research reagent for Research Use Only. It is not for human or animal consumption and is not a medicine, supplement, cosmetic or medical device. Peptworks sells B2B only and does not sell to end consumers.